Bone Health

Hematology

Dermatology

Diabetes

Gastroenterology

Neurology

Oncology

Ophthalmology

Rare Disease

Rheumatology

News

Media

All Videos

Insights

Interviews

Peer Exchange

Podcasts

Compendia

Respiratory

Conferences

Conference Coverage

Conference Listing

CME/CE

Resources

Authors

Biosimilar Resources

Interactive Tools

WHEN CHOICE ARRIVES: Competition & Consequences

Subscribe

E-News

Print Subscription

BIOSIMILAR APPROVALS

Articles

At the American Academy of Dermatology annual meeting, Samsung Bioepis shared positive results from a phase 1 study comparing its ustekinumab biosimilars (SB17) with the reference product (Stealara).

Samsung Bioepis’ Stelara Biosimilar Proves Successful in Phase 1 Study

On this episode of Not So Different, Mark Guyot, senior director of unity provider engagement at McKesson, gives an overview of McKesson’s real-world analysis of community oncology practices and their use of biosimilars and offers advice on overcoming adoption barriers and expanding education efforts.

How Community Oncologists Can Break Down Biosimilar Adoption Barriers

More and more women are becoming pregnant while on anti-tumor necrosis factor (TNF) biosimilars used to treat inflammatory disorders. However, there is “little data” on the safety and effectiveness of biosimilars in pregnancy, according to authors of a recent retrospective study.

Retrospective Study Supports Safety of Anti-TNF Biosimilars During Pregnancy

Videos

Here are the top 5 biosimilar articles for the week of March 13, 2023.

The Top 5 Biosimilar Articles for the Week of March 13

About

Contact

Advisory Board

Do Not Sell My Information

Terms & Conditions

Privacy Policy

Center for Biosimilars®

Facebook

Twitter

LinkedIn

Business Practice

Business

Development

Legal

Policy

Practice

Regulatory

1rem

Business & Practice